vobarilizumab vobarilizumab vobarilizumab (inn; development code alx0061) is a humanized bispecific nanobody (llama-derived heavy-chain only (vhh) antibody) designed for the treatment of inflammatory autoimmune diseases. vobarilizumabmonoclonal antibodytypesingle-chain variable fragmentsourcehumanizedtargetil6rclinical dataother namesalx0061atc codenoneidentifierscas number1628814-88-9chemspidernoneunii9od8iss64ukeggd11005chemical and physical dataformulac1118h1757n315o364s8molar mass25691.68 g·mol−1 this drug was developed by ablynx nv to block interleukin-6 receptor. vobarilizumab has been evaluated in patients with rheumatoid arthritis as well as in lupus.